Bortezomib, thalidomide, dexamethasone, and panobinostat for patients with relapsed multiple myeloma (MUK-six): a multicentre, open-label, phase 1/2 trialRakesh Popat, Jamie Cavenagh, Eric Low et al.|The Lancet Haematology|2016Cited by 43
Bortezomib, Vorinostat, and Dexamethasone Combination Therapy in Relapsed Myeloma: Results of the Phase 2 MUK four TrialSarah Brown, Matthew Jenner, Charlotte Pawlyn et al.|Clinical Lymphoma Myeloma & Leukemia|2020Cited by 22
The MUK five protocol: a phase II randomised, controlled, parallel group, multi-centre trial of carfilzomib, cyclophosphamide and dexamethasone (CCD) vs. cyclophosphamide, bortezomib (Velcade) and dexamethasone (CVD) for first relapse and primary refractory multiple myelomaSarah Brown, Kwee Yong, Samantha Hinsley et al.|BMC Hematology|2016Cited by 9
Extended follow‐up and the feasibility of Panobinostat maintenance for patients with Relapsed Multiple Myeloma treated with Bortezomib, Thalidomide, Dexamethasone plus Panobinostat (<scp>MUK</scp> six open label, multi‐centre phase I/<scp>II</scp> Clinical Trial)Rakesh Popat, Jamie Cavenagh, Sarah Brown et al.|British Journal of Haematology|2018Cited by 8
Carfilzomib, Cyclophosphamide and Dexamethasone Is Well Tolerated in Patients with Relapsed/Refractory Multiple Myeloma Who Have Received One Prior RegimenKwee Yong, Catherine Williams, Sarah Brown et al.|Blood|2015Cited by 6